Eczema Treatment Report

www.EczemaTreatmentReport.com

Phase 1

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT04313400?type=Intr&cond=Eczema&phase=0124&lupd_s=03%2F04%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: 1.1% w/w AMTX-100 CF;   Drug: 0.33% w/w AMTX-100 CF;   Drug: 0.11% w/w AMTX-100 CF;   Drug: Placebo
Sponsors:   Amytrx Therapeutics, Inc.;   Amarex Clinical Research
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04313400

FIRST POSTED:
Wed, 18 Mar 2020 12:00:00 EDT

LAST UPDATE POSTED:
03/18/20 10:39AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04313400?type=Intr&cond=Eczema&phase=0124&lupd_s=03%2F04%2F2020&lupd_d=14&sort=nwst

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

https://clinicaltrials.gov/ct2/show/NCT04135560?type=Intr&cond=Eczema&phase=0124&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

DESCRIPTION:
Condition:   Dermatitis Atopic
Interventions:   Drug: PF-07038124 and Vehicle;   Drug: PF-07038124 or vehicle
Sponsor:   Pfizer
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04135560

FIRST POSTED:
Tue, 22 Oct 2019 12:00:00 EDT

LAST UPDATE POSTED:
10/22/19 07:07AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04135560?type=Intr&cond=Eczema&phase=0124&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

A Phase I Clinical Study of Hemay808 in Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT04100642?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F10%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Phase I Clinical Study of Hemay808

DESCRIPTION:
Condition:   Safety Issues
Interventions:   Drug: Hemay808;   Drug: Placebo
Sponsor:   Tianjin Hemay Pharmaceutical Co.,Ltd
Enrolling by invitation

CLINICALTRIALS.GOV IDENTIFIER:
NCT04100642

FIRST POSTED:
Tue, 24 Sep 2019 12:00:00 EDT

LAST UPDATE POSTED:
09/24/19 06:52AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04100642?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F10%2F2019&lupd_d=14&sort=nwst

Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT04090229?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F07%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: ASLAN004;   Drug: ASLAN004 Placebo
Sponsor:   Aslan Pharmaceuticals
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04090229

FIRST POSTED:
Mon, 16 Sep 2019 12:00:00 EDT

LAST UPDATE POSTED:
09/21/19 11:41AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04090229?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F07%2F2019&lupd_d=14&sort=nwst

Back to top